Center for Outcomes Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
JAMA. 2013 Jul 24;310(4):389-97. doi: 10.1001/jama.2013.8272.
Difference in breast cancer survival by race is a recognized problem among Medicare beneficiaries.
To determine if racial disparity in breast cancer survival is primarily attributable to differences in presentation characteristics at diagnosis or subsequent treatment.
DESIGN, SETTING, AND PATIENTS: Comparison of 7375 black women 65 years and older diagnosed between 1991 to 2005 and 3 sets of 7375 matched white control patients selected from 99,898 white potential controls, using data for 16 US Surveillance, Epidemiology and End Results (SEER) sites in the SEER-Medicare database. All patients received follow-up through December 31, 2009, and the black case patients were matched to 3 white control populations on demographics (age, year of diagnosis, and SEER site), presentation (demographics variables plus patient comorbid conditions and tumor characteristics such as stage, size, grade, and estrogen receptor status), and treatment (presentation variables plus details of surgery, radiation therapy, and chemotherapy).
5-Year survival.
The absolute difference in 5-year survival (blacks, 55.9%; whites, 68.8%) was 12.9% (95% CI, 11.5%-14.5%; P < .001) in the demographics match. This difference remained unchanged between 1991 and 2005. After matching on presentation characteristics, the absolute difference in 5-year survival was 4.4% (95% CI, 2.8%-5.8%; P < .001) and was 3.6% (95% CI, 2.3%-4.9%; P < .001) lower for blacks than for whites matched also on treatment. In the presentation match, fewer blacks received treatment (87.4% vs 91.8%; P < .001), time from diagnosis to treatment was longer (29.2 vs 22.8 days; P < .001), use of anthracyclines and taxols was lower (3.7% vs 5.0%; P < .001), and breast-conserving surgery without other treatment was more frequent (8.2% vs 7.3%; P = .04). Nevertheless, differences in survival associated with treatment differences accounted for only 0.81% of the 12.9% survival difference.
In the SEER-Medicare database, differences in breast cancer survival between black and white women did not substantially change among women diagnosed between 1991 and 2005. These differences in survival appear primarily related to presentation characteristics at diagnosis rather than treatment differences.
医疗保险受益人群中,乳腺癌存活率的种族差异是一个公认的问题。
确定乳腺癌存活率的种族差异主要归因于诊断时表现特征的差异,还是后续治疗的差异。
设计、地点和患者:在 SEER-Medicare 数据库中,比较了 1991 年至 2005 年间诊断出的 7375 名 65 岁及以上的黑人女性和从 99898 名白人潜在对照中选择的 3 组 7375 名匹配的白人对照组患者,共 16 个美国监测、流行病学和最终结果 (SEER) 站点的数据。所有患者均接受了随访,直至 2009 年 12 月 31 日,黑人病例患者与 3 个白人对照组在人口统计学(年龄、诊断年份和 SEER 地点)、表现(人口统计学变量加患者合并症和肿瘤特征,如阶段、大小、分级和雌激素受体状态)和治疗(表现变量加手术、放疗和化疗的详细信息)方面进行了匹配。
5 年生存率。
在人口统计学匹配中,黑人的 5 年生存率(55.9%)与白人的 5 年生存率(68.8%)之间的绝对差异为 12.9%(95%置信区间,11.5%-14.5%;P<0.001)。这一差异在 1991 年至 2005 年期间保持不变。在表现特征匹配后,黑人的 5 年生存率绝对差异为 4.4%(95%置信区间,2.8%-5.8%;P<0.001),而在接受治疗的情况下,黑人的 5 年生存率比白人低 3.6%(95%置信区间,2.3%-4.9%;P<0.001)。在表现匹配中,黑人接受治疗的比例较低(87.4%比 91.8%;P<0.001),从诊断到治疗的时间较长(29.2 天比 22.8 天;P<0.001),使用蒽环类药物和紫杉类药物的比例较低(3.7%比 5.0%;P<0.001),且单纯乳房切除术而不进行其他治疗的比例较高(8.2%比 7.3%;P=0.04)。然而,与治疗差异相关的生存差异仅占 12.9%生存差异的 0.81%。
在 SEER-Medicare 数据库中,1991 年至 2005 年间诊断的黑人女性和白人女性之间的乳腺癌存活率差异在女性中并未发生实质性变化。这些生存差异似乎主要与诊断时的表现特征有关,而不是治疗差异。